HealthcareServices

Revenue of the Precision Genomic Testing Market Predicted to Achieve $25.71 Billion by 2030, Driven by 11.3% CAGR

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the precision genomic testing market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Precision Genomic Testing Market reach by 2030 starting from 2026 levels?

The precision genomic testing market size has experienced swift expansion in recent years. It is projected to increase from $15 billion in 2025 to $16.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.7%. This historical growth can be attributed to advancements in sequencing technologies, the expansion of precision oncology programs, greater availability of genomic databases, an increase in clinical research funding, and rising awareness of genetic disorders.

The precision genomic testing market is projected to experience swift expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $25.71 billion, exhibiting a compound annual growth rate (CAGR) of 11.3%. This projected growth during the forecast period is fueled by several factors, including the wider acceptance of precision medicine, an increase in genomic research investments, the expansion of large-scale genomic projects, a heightened need for companion diagnostics, and the greater incorporation of genomics into standard clinical procedures. Key trends expected during this period involve the increasing uptake of next-generation sequencing, the growing application of AI-powered genomic interpretation, a surging requirement for customized treatment plans, the broadening scope of clinical genomic testing, and improved integration of bioinformatics platforms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25883&type=smp

Which Drivers Are Influencing Long-Term Growth In The Precision Genomic Testing Market?

The increasing occurrence of genetic disorders is anticipated to fuel the expansion of the precision genomic testing market in the future. Genetic disorders are health issues resulting from irregularities in a person’s DNA, encompassing single or multiple gene mutations, or alterations in chromosome count or structure. This rising prevalence largely stems from an increase in maternal age, given that older mothers face a greater likelihood of transmitting chromosomal abnormalities, such as Down syndrome, to their offspring. Precision genomic testing facilitates the early identification and precise diagnosis of genetic conditions by pinpointing particular genetic mutations, thereby enabling focused interventions and customized treatment plans. For instance, in May 2025, Gene People, a registered charity based in the UK, reported that an estimated 1 in 25 children are affected by genetic conditions, impacting more than 2.4 million children and adults across the UK. Furthermore, approximately 30,000 newborns and children in the UK receive a diagnosis of a genetic condition annually. Consequently, the increasing prevalence of genetic disorders is a key factor propelling the growth of the precision genomic testing market.

How Is The Precision Genomic Testing Market Divided Into Segments?

The precision genomic testing market covered in this report is segmented –

1) By Product And Service: Consumables, Equipment, Services

2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, Clustered Regularly Interspaced Short Palindromic Repeats Or Clustered Regularly Interspaced Short Palindromic Repeats-Associated Systems, Other Technologies

3) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Other Applications

4) By End-Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End-Users

Subsegments:

1) By Consumables: Reagents And Kits, Deoxyribonucleic Acid Or Ribonucleic Acid Extraction Kits, Library Preparation Kits, Sequencing Reagents, Polymerase Chain Reaction Assay Kits, Buffers And Enzymes

2) By Equipment: Next-Generation Sequencing Systems, Polymerase Chain Reaction Machines, Microarray Instruments, Deoxyribonucleic Acid Analyzers, Bioinformatics Workstations, Laboratory Automation Systems

3) By Services: Genomic Data Analysis Services, Laboratory Testing Services, Genetic Counseling Services, Clinical Interpretation Services, Contract Research Services, Custom Assay Development Services

How Are New Market Trends Shaping The Landscape Of The Precision Genomic Testing Market?

Leading firms within the precision genomic testing sector are prioritizing the creation of advanced solutions, specifically ultra-sensitive circulating tumor deoxyribonucleic acid assays, to facilitate earlier and more precise cancer detection. These ultra-sensitive circulating tumor deoxyribonucleic acid assays are sophisticated diagnostic tools capable of identifying minute traces of DNA originating from tumors within a patient’s bloodstream, thereby allowing for prompt and accurate recognition of genetic mutations associated with cancer. An example of this innovation is Natera Inc., a US-based clinical genetic testing company, which introduced its ultra-sensitive Signatera genome molecular residual disease test in April 2025. This particular test constructs a customized assay by employing whole genome sequencing on both the patient’s tumor and corresponding normal deoxyribonucleic acid, allowing for the detection of circulating tumor deoxyribonucleic acid even at incredibly low concentrations, as precise as 1 part per million. Such exceptional sensitivity contributes to the earlier and more accurate identification of recurring cancer, ultimately improving the formulation of treatment plans and the overall management of patients across diverse cancer forms.

Which Leading Companies Dominate The Precision Genomic Testing Market Share?

Major companies operating in the precision genomic testing market are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., GenScript Biotech Corporation, Fulgent Genetics Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Ambry Genetics Corporation, Color Health Inc., Pacific Biosciences, Eurofins Genomics LLC, BGI Genomics Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/precision-genomic-testing-global-market-report

How Does The Precision Genomic Testing Market Perform Across Major Global Regions?

North America was the largest region in the precision genomic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precision genomic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Precision Genomic Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25883&type=smp

Browse Through More Reports Similar to the Global Precision Genomic Testing Market 2026, By The Business Research Company

Precision Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/precision-diagnostics-global-market-report

Dna Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/dna-testing-global-market-report

Genomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795